DOCSLIB.ORG

Managing the Patient with Atrial Fibrillation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Managing the Patient with Atrial Fibrillation LONG-TERM TREATMENT Stand-Alone Surgical Ablation: Patient Presentation—Asymptomatic: Rate control alone typically Stand-alone surgical ablation may be considered for patients with paroxysmal, recommended. Symptoms of AF may be subtle and include a sense of persistent, or longstanding persistent symptomatic AF refractory or intolerant fatigue or decreased exercise tolerance. Older patients often attribute these to at least one Class 1 or 3 antiarrhythmic who have failed catheter ablation to aging. Many practitioners attempt to restore sinus rhythm to reassess a or have not failed catheter ablation but prefer a surgical approach (Class IIb patient’s symptom status before abandoning a rhythm control strategy. indication). Stand-alone surgical ablation is not recommended prior to initiation 2 Patient Presentation—Symptomatic: Obtain rate control. If symptoms of antiarrhythmic drug therapy with a Class 1 or 3 antiarrhythmic agent. persist, refer to electrophysiologist or cardiologist for rhythm control Pocket Guide with drugs or ablation. Rhythm control strategies do not obviate the need for anticoagulation. Decision for anticoagulation should be made based on the risks Rate Control outlined above. Drugs: Beta-blockers; Ca-channel blockers (verapamil or diltiazem); digoxin. Managing the Patient with (Digoxin is rarely an effective rate control agent as a single drug.) 1. Fuster, V, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation, 2006. 114(7): p. e257-354. If drugs fail, may consider ablation of AV node and pacemaker: Improves 2. Calkins, H, et al. 2012 HRS/EHRA/ECAS Expert consensus statement on catheter and Atrial Fibrillation symptoms but not mortality. surgical ablation of atrial fibrillation. Heart Rhythm. 2012 Mar 1. [Epub ahead of print]. HR control considered adequate if resting heart rates < 110bpm.13 3. Mittal, S, Movsowitz C, and Steinberg JS. Ambulatory external electrocardiographic monitoring: focus on atrial fibrillation. J Am Coll Cardiol. 2011 Oct 18;58(17)1741-9. Rhythm Control 4. Hart, RG and JL Halperin. Atrial fibrillation and thromboembolism: a decade of Drugs: progress in stroke prevention. Ann Intern Med, 1999. 131(9):688-95. UPDATED APRIL 2012 Normal hearts: Any antiarrhythmic drug. Consider referral to electrophysiologist 5. Connolly, S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J if the patient has impaired renal or hepatic function. Med 2009 Sep 17; 361(12):1139-1151. 6. Patel, MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Structural heart disease or CAD: Sotalol, dofetilide, amiodarone, dronedarone. Med. 2011 Sep 8;365(10):883-91. Amiodarone is not considered a first-line antiarrhythmic medication except in patients with heart failure or substantial hypertrophy. 7. Xarelto (rivaroxaban) package insert (revised), December 2011. 8. Granger, CB, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J CHF: Amiodarone, dofetilide. Med. 2011 Sep 15;365(11):981-92. Two-year success rate: Amiodarone ~60%; other drugs ~40%. 9. Camm, AJ, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Catheter Ablation: European Heart Journal. 2010 Oct; 31(19):2369–2429. Is recommended for patients with symptomatic paroxysmal AF (PAF) who are 10. Lip, GY, et al. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010 refractory or intolerant to at least one Class 1 or 3 antiarrhythmic medication.2 Jun;123(6):484-8. Most success with PAF but can be used to treat AF of any duration (Class IIa 11. Gage, BF, et al. Validation of clinical classification schemes for predicting stroke: results indication for persistent AF, Class IIb indication for longstanding persistent AF).2 from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–2870. 12. Lip, GY, et al. Identifying patients at high risk for stroke despite anticoagulation: a Success rate approximately 70-80% in PAF, lower in persistent AF. comparison of contemporary stroke risk stratification schemes in an anticoagulated Recurrences of AF (or AT) after index AF ablation procedures leads to repeat atrial fibrillation cohort. Stroke. 2010 Dec; 41(12):2731-8. 14 ablation in 20%-40% of patients. 13. Van Gelder, IC, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010 Apr 15; 362(15):1363-73. Concomitant Surgical Ablation: 14. Kobza, R, et al. Late recurrent arrhythmias after ablation of atrial fibrillation: incidence, Surgical ablation is reasonable for patients with paroxysmal, persistent, or mechanisms, and treatment. Heart Rhythm. Dec 2004;1(6):676–683. longstanding persistent symptomatic AF who are undergoing surgery for other indications prior to initiation of a Class I or 3 antiarrhythmic medication (Class Editor IIa indication) and may also be considered for longstanding persistent AF Stephen R. Shorofsky, MD, Ph.D. patients who have not yet failed antiarrhythmic therapy (Class IIb indication).2 Visit www.HRSonline.org/AF to learn more about the Society’s Atrial Fibrillation Disease Assistant Editors State Initiative and view resources for physicians and patients. Anastasios Saliaris, MD Shawn Robinson, MD The Heart Rhythm Society’s Atrial Fibrillation Disease State Initiative is supported in part by Boehringer Ingelheim, Janssen Pharmaceuticals, Inc., and St. Jude Medical. ©2012 Heart Rhythm Society www.HRSonline.org 1 DEFINITION • Transthoracic echocardiogram, to identify valvular heart disease, LA and RA size, CHADS Risk Criteria Points LV size and function. 2 • Uncoordinated atrial activation with consequent deterioration of atrial Congestive heart failure 1 mechanical function. • Blood tests of thyroid, renal, and hepatic function. Hypertension 1 CLASSIFICATION2 ACUTE TREATMENT Age > 75 years 1 • Paroxysmal: Recurrent AF (≥ 2 episodes) that terminates spontaneously within 7 • Hemodynamically unstable: Diabetes mellitus 1 days. Episodes of AF of ≤ 48 hours’ duration that are terminated with electrical — Sedate if possible and perform an immediate cardioversion. Prior stroke or TIA 2 or pharmacologic cardioversion should also be classified as paroxysmal AF. — If refractory to cardioversion: IV amiodarone, ibutilide, or procainamide. • Persistent: AF that is sustained > 7 days. Episodes of AF which are terminated by • Hemodynamically stable: Risk Category Recommended Therapy electrical or pharmacologic cardioversion after ≥ 48 hours of AF, but prior to 7 No risk factors Aspirin, 81 to 325 mg daily or no therapy.* No therapy preferred.9 days, should also be classified as persistent AF episodes. — Anticoagulation and rate control. — If first occurrence, consider cardioversion after adequate anticoagulation 1 point Aspirin, 81 to 325 mg daily, or oral anticoagulant** • Longstanding persistent: Continuous AF of > 1 year duration. (four weeks) or no clot seen on TEE while therapeutically anticoagulated. 2 or more points Oral anticoagulant** • Permanent: AF for which decision has been made, by the patient and the physician — If multiple occurrences, consider referral to electrophysiologist. treating the AF, not to pursue restoration of sinus rhythm by any means. • Consider admission if history suggests a precipitating event CHA DS -VASc Risk Criteria9,10 Points (e.g., acute MI, PE, CHF, etc.). 2 2 EPIDEMIOLOGY1 — Rule out secondary causes (listed above) based on history. Congestive heart failure/LV dysfunction 1 • Most common arrhythmia in clinical practice. — Perform evaluation as stated above. Hypertension 1 • Prevalence: 0.4% to 1% in general population, increasing with age to 8% Age > 75 years 2 in those > 80 yrs. GOALS OF LONG-TERM TREATMENT Diabetes mellitus 1 • Mortality: ~2x that of patients in normal sinus rhythm. • Anticoagulation to prevent stroke. Prior stroke, TIA, thromboembolism 2 • Stroke rate: ~5% per year; higher in patients with valvular heart disease • Improvement in symptoms, functional capacity, and quality of life. Peripheral vascular disease or coronary artery disease 1 (5x increase in relative risk). • Prevention of tachycardia-induced cardiomyopathy. Age > 65 years 1 1,2 PATHOPHYSIOLOGY STROKE RISK AND PREVENTION4 Sex category (i.e., female sex) 1 • AF may be triggered by a focal source of rapid atrial electrical depolarization, • AF is an independent risk factor for stroke. often in the pulmonary veins. It is sustained by the presence of multiple Risk Category Recommended Therapy • Risk of stroke varies based on the presence of the CHADS or CHA DS -VASc reentrant wavelets. 2 2 2 No risk factors Aspirin, 81 to 325 mg daily or no therapy.* No therapy preferred.9 risk factors listed below. The risk of stroke is also increased significantly in RELATED CONDITIONS patients with mitral stenosis or mechanical heart valves. 1 point Aspirin, 81 to 325 mg daily, or oral anticoagulant** • AF may be trigged by acute, temporary causes, including alcohol intake • Long-term anticoagulation with a systemic anticoagulant (warfarin or an 2 or more points Oral anticoagulant** Xa or direct thrombin inhibitor) is indicated in patients with a CHADS or (“holiday heart syndrome”), surgery, electrocution, MI, pericarditis, myocarditis, 2 * Aspirin or no therapy is acceptable for patients < 60 years old and no heart disease (lone AF). CHA DS -VASc score of ≥ 2. The CHA DS -VASc risk score places greater pulmonary embolism, or hyperthyroidism.
Load more

Recommended publications
  • The Holiday Heart Syndrome
    2015/2016 Inês dos Santos Marques Alcohol and the heart março, 2016 Inês dos Santos Marques Alcohol and the heart Mestrado Integrado em Medicina Área: Cardiologia Tipologia: Monografia Trabalho efetuado sob a Orientação de: Doutor Manuel Belchior Campelo Trabalho organizado de acordo com as normas da revista: Revista Portuguesa de Cardiologia março, 2016 “Não sou mas hei de ser…” “E estou cada vez mais perto de ser…” Alcohol and the heart Álcool e coração Inês Marques1, Manuel Campelo1, 2 1Faculdade de Medicina da Universidade do Porto, Porto, Portugal 2Serviço de Cardiologia, Centro Hospitalar de São João, Porto, Portugal Corresponding author: Manuel Campelo, MD, PhD Mail: [email protected] Phone: +351 963 972 116 Number of words in the manuscript, excluding the table: 4932 1 Resumo Alguns dos efeitos benéficos da ingestão de álcool são já razoavelmente conhecidos. Contudo, os seus potenciais efeitos nefastos carecem ainda de avaliação mais detalhada. A caraterização desses efeitos em populações e contextos específicos é ainda escassa, particularmente em jovens adultos e em situações de consumo agudo e/ou em grandes quantidades. A síndroma do coração do fim-de-semana diz respeito ao desenvolvimento de uma arritmia cardíaca durante ou após o consumo agudo de uma grande quantidade de álcool, em indivíduo aparentemente saudável, e que normalmente reverte espontaneamente após um período de abstinência. Este trabalho pretende rever o estado da arte relativamente à síndroma do coração de fim-de-semana, nomeadamente nos jovens adultos. Foram selecionados na PubMed artigos referentes ao consumo de álcool no jovem e ao desenvolvimento de arritmias cardíacas. Nos adultos jovens observa-se uma acentuada heterogeneidade, no que respeita aos hábitos de consumo etílico.
    [Show full text]
  • Atrial Fibrillation
    Cardiology Research and Practice Atrial Fibrillation Guest Editors: Natig Gassonov, Evren Caglayan, Firat Duru, and Fikret Er Atrial Fibrillation Cardiology Research and Practice Atrial Fibrillation Guest Editors: Natig Gassonov, Evren Caglayan, Firat Duru, and Fikret Er Copyright © 2013 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “Cardiology Research and Practice.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board Atul Aggarwal, USA H. A. Katus, Germany J. D. Parker, Canada Jesus´ M. Almendral, Spain Hosen Kiat, Australia Fausto J. Pinto, Portugal Peter Backx, Canada Anne A. Knowlton, USA Bertram Pitt, UK J Brugada, Spain GavinW.Lambert,Australia Robert Edmund Roberts, Canada Ramon Brugada, Canada Chim Choy Lang, UK Terrence D. Ruddy, Canada Hans R. Brunner, Switzerland F. H H Leenen, Canada Frank T. Ruschitzka, Switzerland Vicky A. Cameron, New Zealand Seppo Lehto, Finland Christian Seiler, Switzerland David J. Chambers, UK John C. Longhurst, USA Sidney G. Shaw, Switzerland Robert Chen, Taiwan Lars S. Maier, Germany Pawan K. Singal, Canada Mariantonietta Cicoira, Italy Olivia Manfrini, Italy Felix C. Tanner, Switzerland Antonio Colombo, Italy Gerald Maurer, Austria Hendrik T. Tevaearai, Switzerland Omar H. Dabbous, USA G. A. Mensah, USA G. Thiene, Italy Naranjan S. Dhalla, Canada Robert M. Mentzer, USA H. O. Ventura, USA Firat Duru, Switzerland Piera Angelica Merlini, Italy Stephan von Haehling, Germany Vladim´ır Dzavˇ ´ık, Canada Marco Metra, Italy James T. Willerson, USA Gerasimos Filippatos, Greece Veselin Mitrovic, Germany Michael S.
    [Show full text]
  • EKG Zmeny Pri Akútnej Intoxikácii Alkoholom
    Přehledný referát EKG zmeny pri akútnej intoxikácii alkoholom K. Trejbal, P. Mitro III. interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura Košice, Slovenská republika, prednosta doc. MUDr. Peter Mitro, Ph.D. Súhrn: U pacientov s akútnou intoxikáciou etylalkoholom sú často prítomné patologické zmeny elektrokardiogramu (EKG). Časte- jšie a prognosticky závažnejšie bývajú u chronických alkoholikov, pacientov s ischemickou chorobou srdca (ICHS), alkoholovou kardiomyopatiou, alebo iným organickým ochorením srdca, môžu sa však vyskytovať aj u mladých a zdravých jedincov. Typické EKG zmeny pri ebriete sú poruchy srdcového rytmu, a to jednak charakteru porúch tvorby vzruchu, tak aj patologického vedenia vzruchu. U ľudí bez klinického dôkazu srdcového ochorenia ich zaraďujeme pod tzv. „holiday heart syndrome“. Najčastejšia tachyarytmia je fibrilácia predsiení, zriedkavejšia, ale prognosticky podstatne závažnejšia, je polymorfná komorová tachykardia typu torsades de pointes (TdP). Z bradyarytmií je najvýznamnejšia alkoholom indukovaná sínusová bradykardia, ktorá sa môže prejaviť opakovanými synkopami. So stúpajúcou hladinou alkoholu v krvi sa zvyšuje výskyt signifikantného predĺženia jednotlivých EKG intervalov, s mož- nou manifestáciou latentnej prevodovej poruchy, či dokonca náhlej srdcovej smrti. V EKG obraze sa okrem porúch rytmu veľmi často zistia nešpecifické zmeny repolarizácie. U pacientov s ICHS dochádza pri alkoholovej intoxikácii k prehĺbeniu ischémie, ktorá prebie- ha väčšinou asymptomaticky ako tichá ischémia myokardu. Výsledný EKG obraz môžu výrazne ovplyvniť stavy, ktoré sa neraz vysky- tujú súčasne s opitosťou, ako napr. hypotermia, hypoglykémia či elektrolytová dysbalancia. Podobné EKG zmeny ako pri akútnej alkoholovej intoxikácii, vznikajú aj pri akútnom abstinenčnom syndróme, najmä pri delíriu tremens. Existujú presvedčivé dôkazy o tom, že nielen chronický alkoholizmus, ale aj nárazové pitie je spojené so zvýšením kardiovaskulárnej mortality.
    [Show full text]
  • Variance in Clinical Profile and Use of Anticoagulants in Valvular and Non Valvular Atrial Fibrillation
    World Journal of Cardiovascular Diseases, 2020, 10, 488-499 https://www.scirp.org/journal/wjcd ISSN Online: 2164-5337 ISSN Print: 2164-5329 Variance in Clinical Profile and Use of Anticoagulants in Valvular and Non Valvular Atrial Fibrillation Smriti Shakya*, Arun Sayami, Ratna Mani Gajurel, Chandra Mani Poudel, Hemant Shrestha, Surya Devkota, Sanjeev Thapa, Rajaram Khanal Department of Cardiology, Manmohan Cardiothoracic Vascular and Transplant Centre (MCVTC), Institute of Medicine, TUTH, Kathmandu, Nepal How to cite this paper: Shakya, S., Sayami, Abstract A., Gajurel, R.M., Poudel, C.M., Shrestha, H., Devkota, S., Thapa, S. and Khanal, R. (2020) Introduction: Atrial fibrillation is the most common cardiac arrhythmia en- Variance in Clinical Profile and Use of An- countered in clinical practice that affects morbidity and mortality to a large ticoagulants in Valvular and Non Valvular extent. This study was intended to determine various clinical profile and eti- Atrial Fibrillation. World Journal of Cardi- ological factors in valvular and non-valvular atrial fibrillation and evaluate ovascular Diseases, 10, 488-499. https://doi.org/10.4236/wjcd.2020.107049 the usage of anticoagulants in them in the settings of developing nation like ours. Methods: A hospital based cross-sectional observational prospective Received: June 29, 2020 study was conducted at Manmohan Cardiothoracic Vascular and Transplant Accepted: July 24, 2020 Center, Institute of Medicine, Nepal for a period of sixteen months. All the Published: July 27, 2020 patients with atrial fibrillation who were admitted in the cardiology depart- Copyright © 2020 by author(s) and ment were included. The demographic profile, etiology, clinical features and Scientific Research Publishing Inc.
    [Show full text]
  • Holiday Heart Syndrome Revisited After 34 Years
    FACULDADE DE MEDICINA DA UNIVERSIDADE DE COIMBRA TRABALHO FINAL DO 6º ANO MÉDICO COM VISTA À ATRIBUIÇÃO DO GRAU DE MESTRE NO ÂMBITO DO CICLO DE ESTUDOS DE MESTRADO INTEGRADO EM MEDICINA DAVID MANUEL MARQUES PINTO TONELO HOLIDAY HEART SYNDROME REVISITED AFTER 34 YEARS ARTIGO DE REVISÃO ÁREA CIENTÍFICA DE CARDIOLOGIA TRABALHO REALIZADO SOB A ORIENTAÇÃO DE: RUI ANDRÉ QUADROS BEBIANO DA PROVIDÊNCIA E COSTA SETEMBRO 2012 Holiday Heart Syndrome revisited after 34 years David Tonelo BSc*, Rui Providência MD MSc, Lino Gonçalves MD PhD FESC Faculty of Medicine, University of Coimbra, Portugal Abstract Cardiovascular effects of ethanol have been known for a long time. However most research has focused on beneficial effects (the “French--Paradox”) when consumed moderately or its harmful consequences, such as dilated cardiomyopathy, when heavily consumed for a long time. An association between acute alcohol ingestion and onset of cardiac arrhythmias was first reported in early 70’s. In 1978 Phill Ettinger described for the first time “Holiday Heart Syndrome” as the occurrence, in healthy people without heart disease known to cause arrhythmia, of an acute cardiac rhythm disturbance, most frequently atrial fibrillation, after binge drinking. This name derived from the fact episodes were initially observed more frequently after weekends or public holidays. Thirty-four years have passed since original description of “Holiday Heart Syndrome”, with new research in this field, increasing the knowledge about this entity. Throughout this paper the authors will comprehensively review most of the available data concerning the “Holiday Heart Syndrome” and highlight the currently unsolved questions. Keywords: Holiday Heart Syndrome; Alcohol; Cardiac arrhythmia *Corresponding author: Tel: +351 918820405; E-mail address: [email protected] (D.Tonelo) 22 Introduction Alcohol is one of the oldest known drugs and it’s the most used recreational drug in the United States of America1 and probably in the rest of the globe.
    [Show full text]
  • Consensus and Controversy in the Debate Over the Biphasic Impact of Alcohol Consumption on the Cardiovascular System
    nutrients Review Consensus and Controversy in the Debate over the Biphasic Impact of Alcohol Consumption on the Cardiovascular System 1,2 2, 3 1,2 Cristian Stătescu , Alexandra Clement *, Ionela-Lăcrămioara S, erban and Radu Sascău 1 Internal Medicine Department, “Grigore T. Popa” University of Medicine and Pharmacy, 700503 Ias, i, Romania; [email protected] (C.S.); [email protected] (R.S.) 2 Cardiology Department, Cardiovascular Diseases Institute “Prof. Dr. George I.M. Georgescu”, 700503 Ias, i, Romania 3 Physiology Department, “Grigore T. Popa” University of Medicine and Pharmacy, 700503 Ias, i, Romania; ionela.serban@umfiasi.ro * Correspondence: [email protected]; Tel.: +40-0232-211-834 Abstract: In the past few decades, research has focused on the importance of addressing modifiable risk factors as a means of lowering the risk of cardiovascular disease (CVD), which represents the worldwide leading cause of death. For quite a long time, it has been considered that ethanol intake has a biphasic impact on the cardiovascular system, mainly depending on the drinking pattern, amount of consumption, and type of alcoholic beverage. Multiple case-control studies and meta- analyses reported the existence of a “U-type” or “J-shaped” relationship between alcohol and CVD, as well as mortality, indicating that low to moderate alcohol consumption decreases the number of adverse cardiovascular events and deaths compared to abstinence, while excessive alcohol use has unquestionably deleterious effects on the circulatory system. However, beginning in the early 2000s, the cardioprotective effects of low doses of alcohol were abnegated by the results of large epidemiological studies. Therefore, this narrative review aims to reiterate the association of alcohol Citation: St˘atescu,C.; Clement, A.; use with cardiac arrhythmias, dilated cardiomyopathy, arterial hypertension, atherosclerotic vascular S, erban, I.-L.; Sasc˘au,R.
    [Show full text]
  • JMSCR Vol||08||Issue||02||Page 367-372||February 2020
    JMSCR Vol||08||Issue||02||Page 367-372||February 2020 http://jmscr.igmpublication.org/home/ ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v8i2.65 Study of aetiology and Clinical Profile in Patients with Atrial Fibrillation Authors Dr Rajaram Yadav1, Dr Madan Paul Singh2* 1Junior Resident, Department of Medicine, Patna Medical College & Hospital 2Professor & HOD, Department of Medicine, Patna Medical College & Hospital *Corresponding Author Dr Madan Paul Singh Abstract Incidence of AF is Age and Sex related, and ranges from 0.1% per year before the age of 40 years to higher than 1.5% year in women and higher than 2% per year in men older than 80 years. Life time risk of developing AF is approximately 25% for individuals 40 years old. In Framingham heart study AF developed 1.5 times more in men than in women. Aims: To find out possible underlying predisposing factors for Atrial fibrillation, both cardiac and non- cardiac in our population. Methods: The present study was conducted upon 60 patients with Atria Fibrillationin the Department of Medicine, Patna Medical College and Hospital, Patna, to find out the varied presenting symptoms of Atrial fibrillation and possible underlying predisposing factors for Atrial fibrillation. Study period was June, 2017 to December, 2019. Results: People are more likely to be affected by fibrillation between the age of 40 to 60 years. There was female predominance in our study with a male to female ratio of 1.8:1. Palpitation was commonest presenting complaint found in the present study followed by dyspena, chest pain, abdominal pain, tremor, dizziness, and leg swelling.
    [Show full text]
  • 1 Natural History of Coagulopathy and Use Of
    NATURAL HISTORY OF COAGULOPATHY AND USE OF ANTI-THROMBOTIC AGENTS IN COVID-19 PATIENTS AND PERSONS VACCINATED AGAINST SARS-COV-2 Principal Investigators Prof Dani Prieto-Alhambra (University of Oxford) Associate Prof Katia Verhamme (EMC) Associate Prof Peter Rijnbeek (EMC) Document Status Date of final version of the study Protocol ver 1.0 report EU PAS register number EUPAS40414 1 PASS information Title Natural history of coagulopathy and use of anti-thrombotic agents in COVID-19 patients and persons vaccinated against SARS-CoV-2 Protocol version identifier 1.0 Date of last version of protocol 12/04/2021 EU PAS register number EUPAS40414 Active Ingredient n/a Medicinal product J07BX Product reference n/a Procedure number n/a Marketing authorisation holder(s) n/a Joint PASS n/a Research question and objectives 1) To estimate the background incidence of selected embolic and thrombotic events of interest among the general population. 2) To estimate the incidence of selected embolic and thrombotic events of interest among persons vaccinated against SARS-CoV-2 at 7, 14, 21, and 28 days. 3) To estimate incidence rate ratios for selected embolic/thrombotic events of interest amongst people vaccinated against SARS-CoV-2 compared to background rates as estimated in Objective #1. 4) To estimate the incidence of venous thromboembolic events among patients with COVID-19 at 30-, 60-, and 90-days. 5) To calculate the risks of COVID-19 worsening stratified by the occurrence of a venous thromboembolic event. 6) To assess the impact of risk factors on the rates of venous thromboembolic events among patients with COVID-19.
    [Show full text]
  • Alcoholic Cardiomyopathy: a Review
    Thomas Jefferson University Jefferson Digital Commons Division of Cardiology Faculty Papers Division of Cardiology 10-1-2011 Alcoholic cardiomyopathy: a review. Anil George Einstein Institute for Heart and Vascular Health, Albert Einstein Medical Center Vincent M Figueredo Jefferson Medical College Follow this and additional works at: https://jdc.jefferson.edu/cardiologyfp Part of the Cardiology Commons Let us know how access to this document benefits ouy Recommended Citation George, Anil and Figueredo, Vincent M, "Alcoholic cardiomyopathy: a review." (2011). Division of Cardiology Faculty Papers. Paper 11. https://jdc.jefferson.edu/cardiologyfp/11 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Division of Cardiology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [email protected]. As submitted to: Journal of Cardiac Failure And later published as: Alcoholic Cardiomyopathy: A review. Volume 17, Issue 10, October 2011, Pages 844-849 DOI: 10.1016/j.cardfail.2011.05.008 Anil George, MD 1, Vincent M. Figueredo, MD 1,2 1 Einstein Institute for Heart and Vascular Health, Albert Einstein Medical Center and 2Jefferson Medical College, Philadelphia Key words: cardiomyopathy, alcohol, heart failure, systolic dysfunction, diastolic dysfunction Address correspondence to: Vincent M.
    [Show full text]
  • Heart Beat Volume 9 No
    Heart Beat Volume 9 No. 1 Salinas Valley Mended Hearts Chapter 370 Jan - March 2020 Officers: Happy New Year President: Julie Jezowski to all [email protected] from Mended Hearts Vice President: Al Stream [email protected] The Earth begins another trip around the sun Janu- Secretary: Karen Humphrey ary 1, and we'll travel more than 583 million miles [email protected] (tired yet?) in 365.24 days. Treasurer & Arron Yaras This is also leap year! Newsletter: [email protected] This day has been observed as New Year's Day in most English-speaking countries since the British Cal- endar Act of 1751. Before that time, the New Year began on March 25, about the date of the vernal equi- Our Visitors Are nox. Monday: Al & Marilyn Stream January 1 is a day when people resolve to make Wednesday: Shirley Gould improvements in the coming year. So, it is a great Thursday: Arron Yaras & Julie Jezowski time to renew our commitment to health and happi- Friday: Tom & Karen Humphrey ness! Saturday: Alex Sapien & Bob Hansen Cardiac Wellness: Jim Eddy & Wayne Tucker Here's hoping you have a safe new year filled with From January 1 to December 31, we have love, health, hope, and prosperity! made 1,193 patient visits and 33 family only visits for a total of 1,226 visits. Upcoming Meeting Speakers January 21, 2020 at 6:00 p.m. Our Speaker is Suzette Urquides, DNP, MPA, CCRN SVMH Cardiac Cath Lab Cardiovascular Technology Update Mended Hearts is a non-profit support and continu- February 18, 2020 at 6:00 p.m.
    [Show full text]
  • 1 Natural History of Coagulopathy and Use Of
    NATURAL HISTORY OF COAGULOPATHY AND USE OF ANTI-THROMBOTIC AGENTS IN COVID-19 PATIENTS AND PERSONS VACCINATED AGAINST SARS-COV-2 Principal Investigators Prof Dani Prieto-Alhambra (University of Oxford) Associate Prof Katia Verhamme (EMC) Associate Prof Peter Rijnbeek (EMC) Document Status Date of final version of the study Protocol ver 1.1 report EU PAS register number EUPAS40414 1 PASS information Title Natural history of coagulopathy and use of anti-thrombotic agents in COVID-19 patients and persons vaccinated against SARS-CoV-2 Protocol version identifier 1.1 Date of last version of protocol 07/06/2021 EU PAS register number EUPAS40414 Active Ingredient n/a Medicinal product J07BX Product reference n/a Procedure number n/a Marketing authorisation holder(s) n/a Joint PASS n/a Research question and objectives 1) To estimate the background incidence of selected embolic and thrombotic events of interest among the general population. 2) To estimate the incidence of selected embolic and thrombotic events of interest among persons vaccinated against SARS-CoV-2 at 7, 14, 21, and 28 days. 3) To estimate incidence rate ratios for selected embolic/thrombotic events of interest amongst people vaccinated against SARS-CoV-2 compared to background rates as estimated in Objective #1. 4) To estimate the incidence of venous thromboembolic events among patients with COVID-19 at 30-, 60-, and 90-days. 5) To calculate the risks of COVID-19 worsening stratified by the occurrence of a venous thromboembolic event. 6) To assess the impact of risk factors on the rates of venous thromboembolic events among patients with COVID-19.
    [Show full text]
  • Usmle Step 2 Ck Review ~ Cardiovascular
    USMLE STEP 2 CK REVIEW ~ CARDIOVASCULAR ISCHEMIC HEART DISEASE . Coronary Artery Disease (CAD) o Accumulation of atheromatous plaques within walls of coronary arteries that supply O2 to myocardium . Blood flow causes ischemia of myocardial cells due to lack of oxygen Effects of ischemia reversible if blood flow to heart improved . Complete occlusion of artery causes irreversible cell death called myocardial infarction o Risk Factors: . DM, HTN, tobacco, age >45, hyperlipidemia, LDL, HDL, homocysteine . FHx of premature CAD or MI in 1st-degree relative – men <45yrs & women <55yrs o Clinical Presentation Asymptomatic, stable angina, unstable angina, MI, sudden cardiac death o Canadian Cardiovascular Society (CCS) Angina Classification: . Class I Angina w/strenuous or rapid activity – no angina from ordinary physical activity . Class II Slight limitation of ordinary activity – angina after >2 blocks or >1 flight of stairs . Class III Marked limitation of ordinary activity – angina after <2 blocks or <1 flight of stairs . Class IV Any physical activity causes discomfort – angina may be present at rest o Diagnosis: . Resting ECG: Prior MI Q waves UA ST segment or T-wave abnormalities seen during episode of chest pain . Stress ECG: Recording ECG before, during & after exercise on treadmill 75% sensitive only if able to exercise sufficiently to reach 85% of predicted maximum HR o Predicted maximum HR = 220 − Patient’s age Should undergo cardiac catheterization if results from stress test Positive findings for CAD: o ST elevation Transmural infarct o ST depression Subendocardial ischemia o Failure to exercise >2mins due to symptoms o Hypotension o Ventricular arrhythmia . Stress Echocardiography: Performed before & immediately after exercise – preferred over stress ECG More sensitive in detecting ischemia, can assess LV size, EF & diagnose valvular disease Ischemia evidenced by wall motion abnormalities not seen at rest – akinesis or dyskinesis Should undergo cardiac catheterization if test results .
    [Show full text]